Phase I Clinical Study Of Neumedicines Inc.' Interleukin-12 As A Treatment For Wound Healing And Infections Recommended For Funding By The U.S. Department Of Defense
4/28/2014 11:06:14 AM
PASADENA, Calif.--(BUSINESS WIRE)--Neumedicines Inc., a privately held biotechnology company, announced today that their proposal to conduct a phase I clinical study of recombinant human interleukin-12 (rHuIL-12) for the treatment of traumatic wounds has been recommended for funding subject to negotiations by the Department of Defense (DoD) office of the Congressionally Directed Medical Research Programs (CDMRP).
Help employers find you! Check out all the jobs and post your resume.
comments powered by